Repligen Corporation (RGEN) has a MoatMap StockRank of 38/100 based on Quality (56/100), Value (18/100), and Momentum (52/100) factor scores. The current signal is HOLD. Repligen is a classic Terry Smith 'picks and shovels' compounder for the bioprocessing industry. Its filtration and chromatography products are deeply embedded in FDA-approved manufacturing processes, creating massive switching costs. As CDMOs expand capacity to meet complex biologics demand, Repligen acts as an asset-light toll-booth on global bioprocessing volume without binary drug trial risk.
Repligen Corporation is a leading provider of advanced bioprocessing technologies and consumables essential for the development and commercial manufacturing of biologics and gene therapies. The company's innovative product portfolio, including filtration systems, chromatography media, and protein reagents, establishes it as a critical supplier within the rapidly expanding biopharmaceutical industry. Repligen benefits from proprietary technologies and deep customer embeddedness in vital production workflows.
| Price | $130.13 |
| Market Cap | $6.9B |
| P/E (TTM) | 139.07 |
| P/E (Forward) | 49.71 |
| Price/Book | 3.39 |
| Return on Equity | 2.5% |
| Return on Invested Capital | 3.0% |
| Debt/Equity | 32.66 |
| Gross Margin | 53.1% |
| Operating Margin | 8.9% |
| Revenue Growth | 14.8% |
| Free Cash Flow | $69M |
Repligen Corporation operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).